Literature DB >> 1260168

Reflex bradycardia and hypotension produced by prostaglandin F2alpha in the cat.

M C Koss, J Nakano.   

Abstract

1 Intravenous administration of prostaglandin F2alpha results in a dose-dependent increase in pulmonary arterial pressure, decrease in systemic arterial pressure and a delayed bradycardia. Pulmonary vasoconstriction was observed at doses as low as 0.1 and 0.3 mug/kg. The systemic depressor and heart rate lowering effects were observed at 1 mug/kg doses and above. 2 A moderate bradycardia was still observed after atropine blockade but was abolished following bilateral vagotomy. Neither of these procedures affected the pulmonary vascular response. 3 Injections of submaximal doses of prostaglandin F2alpha (1--4 mug/kg) produced a greater and longer lasting bradycardia when injected into the left atrium than was observed following intravenous administration. In addition the latency of onset was much shorter following left atrial injection. These doses resulted in no change in heart rate and a minimal hypotension when injected into the brachiocephalic artery or into the aortic arch. 4 Small doses of prostaglandin F2alpha administered at the level of the origin of the coronary arteries produced marked decreases in heart rate and blood pressure whereas no change occurred following injection of the same amount into the ascending aorta at more distal sites. 5 These results suggest that prostaglandin F2alpha produces bradycardia and hypotension in the cat by activating 'receptors' located in the left heart or by acting on structures perfused by means of the coronary arteries.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1260168      PMCID: PMC1666936          DOI: 10.1111/j.1476-5381.1976.tb07635.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

Review 1.  Vagal sensory receptors and their reflex effects.

Authors:  A S Paintal
Journal:  Physiol Rev       Date:  1973-01       Impact factor: 37.312

2.  Studies on the mechanism of the hypertensive effect of prostaglandin F2-alpha.

Authors:  D W Ducharme; J R Weeks; R G Montgomery
Journal:  J Pharmacol Exp Ther       Date:  1968-03       Impact factor: 4.030

3.  The effects of prostaglandins E2, A2 and F2 alpha on carotid baroreceptors and chemoreceptors.

Authors:  D S McQueen; C Belmonte
Journal:  Q J Exp Physiol Cogn Med Sci       Date:  1974-01

Review 4.  The prostaglandins: a family of biologically active lipids.

Authors:  S Bergström; L A Carlson; J R Weeks
Journal:  Pharmacol Rev       Date:  1968-03       Impact factor: 25.468

5.  Effects of prostaglandins E 1 and F 2 on the peripheral circulation in the cat.

Authors:  M C Koss; J Nakano
Journal:  Proc Soc Exp Biol Med       Date:  1973-02

6.  Inhibition of adrenergic outflow to peripheral blood vessels by vagal afferents from the cardiopulmonary region in the dog.

Authors:  G Mancia; D E Donald; J T Shepherd
Journal:  Circ Res       Date:  1973-12       Impact factor: 17.367

7.  Cardiovascular actions of prostaglandins E1 and F2 alpha in the cat.

Authors:  M C Koss; J W Gray; M Davison; J Nakano
Journal:  Eur J Pharmacol       Date:  1973-11       Impact factor: 4.432

8.  Metabolism of prostaglandin E 1 in the cerebral cortex and cerebellum of the dog and rat.

Authors:  J Nakano; A V Prancan; S E Moore
Journal:  Brain Res       Date:  1972-04-28       Impact factor: 3.252

9.  Effects of prostaglandins E1 and F2-alpha on systemic, pulmonary, and splanchnic circulations in dogs.

Authors:  J Nakano; B Cole
Journal:  Am J Physiol       Date:  1969-07

10.  Reflex apnea, bradycardia, and hypotension produced by serotonin and phenyldiguanide acting on the nodose ganglia of the cat.

Authors:  L Jacobs; J H Comroe
Journal:  Circ Res       Date:  1971-08       Impact factor: 17.367

View more
  1 in total

1.  Mechanisms of reflex bradycardia and hypotension by metabolites of arachidonic acid in the cat.

Authors:  T H Hintze; G Kaley; M J Panzenbeck
Journal:  Br J Pharmacol       Date:  1984-05       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.